A companion to the broader stress-supplement picture
Our best supplements for stress comparison ranked ashwagandha as the best-studied option across the main stress-marketed ingredients, ahead of magnesium, L-theanine and rhodiola. This goes deeper on ashwagandha specifically: what the trials actually measured, where the standardized extracts differ, and where the evidence gets noticeably thinner than the stress claim.
Ashwagandha (Withania somnifera) is an adaptogenic herb used in Ayurvedic medicine for centuries, but traditional use and modern randomized trial evidence are different kinds of support, and the goal here is to separate claims with real trial data behind them from claims riding on the herb's general reputation.
The cortisol and stress evidence: genuinely strong
This is where ashwagandha's evidence base is most solid. Multiple randomized, placebo-controlled trials using standardized extracts have found consistent reductions in both self-reported stress scores and serum cortisol, the body's primary stress hormone. A widely cited trial using KSM-66 at 600mg/day over roughly 60 days found serum cortisol down close to 28% versus placebo, alongside measurable improvements on standardized stress and anxiety scales.
A 2023 registered clinical trial (listed on ClinicalTrials.gov) specifically evaluating KSM-66 in adults with high stress or anxiety adds to a now-substantial body of placebo-controlled work using this extract. That depth of randomized trial support is unusual for an herbal supplement; most adaptogens have a handful of small trials, ashwagandha has a meaningfully larger and more consistent set.
The effect takes time to show up. Trials typically ran six to eight weeks before measuring the cortisol and stress-score changes, which matches the pattern covered in the broader stress-supplement comparison: this is not a same-day, situational-stress tool like L-theanine, it's a slower-acting correction that needs consistent daily use to evaluate fairly.
KSM-66 vs Sensoril: not interchangeable names
KSM-66 and Sensoril are both patented, standardized root extracts of Withania somnifera, but they're produced through different extraction processes and standardized to different withanolide profiles, the class of compounds believed to be ashwagandha's main active constituents.
KSM-66 is a full-spectrum root extract standardized to a minimum 5% withanolides. Sensoril is typically a root-and-leaf extract standardized to a higher withanolide percentage using a different process, with its own separate body of clinical trials, generally at lower milligram doses than KSM-66 trials since Sensoril is more concentrated per milligram.
A smaller, newer standardized extract, Shoden, has also appeared in more recent trials at notably lower doses (around 120mg/day) while still showing measurable effects, reflecting a higher withanolide concentration per milligram than either KSM-66 or Sensoril.
The label-reading rule that matters: a product listing plain "ashwagandha root powder" or "ashwagandha extract" with no named, patented standardized extract and no withanolide percentage has no direct line to any specific published trial.
The research is attached to the named extract (KSM-66, Sensoril, Shoden) at its studied dose, not to the species name alone. This mirrors the strain-specificity issue covered in our probiotic buying guide: the broad category name tells you less than the specific standardized identity.
| Extract | Typical studied dose | Standardization | Best-studied use |
|---|---|---|---|
| KSM-66 | 300-600mg/day | ≥5% withanolides, root-only | Cortisol, general stress, broad trial base |
| Sensoril | 125-250mg/day | Higher withanolide %, root + leaf | Stress, sleep-adjacent outcomes |
| Shoden | ~120mg/day | Highest withanolide concentration per mg | Newer, smaller trial base, stress and testosterone |
Sleep: real but more modest than the stress claim
Ashwagandha is frequently marketed as a sleep aid, and there is trial evidence supporting a modest improvement in sleep quality and sleep onset, particularly in people with existing insomnia or higher-than-usual stress.
The effect size in most trials is more modest than the cortisol findings. Several of the positive sleep trials used Sensoril specifically, at the lower end of its typical dose range, rather than KSM-66's higher-dose protocol.
The honest framing: ashwagandha is a reasonable secondary option for stress-related sleep difficulty, not a first-line insomnia treatment with the evidence weight of something like magnesium glycinate for sleep tied to a dietary shortfall, or behavioral approaches like CBT-I, which has the strongest evidence base for chronic insomnia specifically.
Testosterone and athletic performance: the weakest marketed claim
This is where ashwagandha marketing gets noticeably ahead of the evidence relative to the stress claims. Some smaller trials, mostly in young, resistance-training men, have found modest increases in testosterone and improvements in strength or muscle mass measures with ashwagandha supplementation. Other trials, including some using similar doses and extracts, found no significant testosterone change. The literature is genuinely split.
The inconsistency across trials, smaller sample sizes, and the fact that most positive findings come from a narrower demographic (young men already in a structured resistance-training program) make this a considerably weaker evidence base than the cortisol and general stress findings. Marketing that presents ashwagandha's testosterone or performance effects with the same confidence as its stress-reduction effects is overstating a genuinely mixed literature.
Thyroid interaction: a real mechanism, not a theoretical one
Ashwagandha has a documented, mechanistically plausible effect on thyroid hormone levels, with some trial and case-report data showing increases in T3 and T4 in people taking it, including in people without a prior thyroid diagnosis.
For someone with hyperthyroidism or Graves' disease, this is a real reason to avoid ashwagandha or use it only under a doctor's supervision. Not a minor theoretical risk: it could plausibly worsen an already-overactive thyroid.
For someone on thyroid hormone replacement (levothyroxine) for hypothyroidism, the interaction cuts the other way, potentially requiring a dose adjustment if ashwagandha shifts thyroid hormone levels upward while already on replacement therapy. Anyone with a diagnosed thyroid condition, in either direction, should loop in their prescribing doctor before adding ashwagandha, not after noticing a symptom change.
Liver injury: rare, but documented in case reports
Multiple published case reports describe acute liver injury temporally associated with ashwagandha supplementation, including a documented case of a previously healthy adult developing jaundice, abnormally high liver enzymes and a significant rise in bilirubin within roughly 30 hours of use, as covered in a case report in PMC and a separate case report series on herbal product liver injury.
This needs context: these are case reports, not findings from controlled trials, and causality in individual case reports is harder to establish definitively than a trial result. The broader population of ashwagandha users is large relative to the small number of published cases.
A separate 12-month prospective observational study of KSM-66 at 600mg/day found no measurable adverse effect on liver, kidney, or thyroid function over that duration, which is reassuring for the standardized-extract, standard-dose use case specifically.
The practical takeaway is not that ashwagandha is broadly liver-toxic, the long-term safety data on standardized extracts at studied doses is reasonably reassuring, but that an unusual reaction (jaundice, unexplained fatigue, dark urine, abdominal pain) after starting it is not something to dismiss, and is worth stopping the supplement and seeking care for rather than waiting out.
Pregnancy, autoimmune conditions, and who else should avoid it
Ashwagandha is contraindicated in pregnancy. Full stop. Traditional Ayurvedic use and some animal data raise concerns about uterine stimulation and miscarriage risk, and there is no human trial safety data that would override that caution; this is a clear-cut avoid, not a case-by-case judgment call.
Because ashwagandha has immune-modulating effects, people with autoimmune conditions (rheumatoid arthritis, lupus, Hashimoto's) should discuss it with their doctor before starting. Stimulating immune activity is a plausible risk in that population, even though it's not definitively proven.
The same caution applies to anyone already taking sedatives, blood-pressure medication, or thyroid medication, given ashwagandha's own modest blood-pressure-lowering and thyroid-hormone-shifting effects covered above. Introducing it alongside those medications without medical input risks compounding effects that are hard to separate out.
Dosage and timing in practice
Most of the positive stress and cortisol trials used 300 to 600mg/day of KSM-66, or 125 to 250mg/day of Sensoril, taken consistently for six to eight weeks before assessing effect; doses above roughly 1,250mg/day have little supporting data and aren't recommended simply because more hasn't been shown to be better.
Time of day is less rigorously established in the literature than the dose question. Since several trials associate ashwagandha with modest sedative and sleep-supportive effects, taking it in the evening is a reasonable default for most people, particularly if sleep is one of the target outcomes.
Morning dosing hasn't been shown to blunt the stress or cortisol effects in the trials that measured them. If you notice daytime drowsiness, shifting to evening dosing is the simplest fix.